TrialBlood neoplasia2024

KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study.

Hiroshi Ureshino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.